Core Viewpoint - Neuralink, led by Elon Musk, is making significant advancements in the brain-computer interface (BCI) field, with plans to enhance its technology and expand its applications in the coming years [2][3][20]. Company Developments - As of June 27, Neuralink has seven participants in its trials, including four with spinal cord injuries and three with amyotrophic lateral sclerosis (ALS), who are using the devices for an average of 50 hours per week, with peaks exceeding 100 hours [5][10]. - The company aims to implant devices in the speech cortex by Q4 2025 to decode silent "intent speech" and plans to increase the number of electrodes in implants to 3,000 by 2026 [12][13]. - By 2027, the number of electrodes is expected to reach 10,000, allowing for multiple device implants across different brain areas [14]. - The ultimate goal is to create a "full brain interface" that connects biological brains with external machines, potentially revolutionizing the treatment of neurological diseases and enhancing human capabilities [16][17]. Industry Insights - The global BCI market is projected to grow at a compound annual growth rate (CAGR) of 25.22%, reaching $7.63 billion from 2025 to 2029 [3][22]. - The market size increased from $1.2 billion in 2019 to $1.98 billion in 2023, with expectations to reach $2.48 billion in 2024, reflecting a growth rate of 25.25% [21]. - The medical health sector is currently the most developed area for BCI applications, with potential market sizes ranging from $15 billion to $85 billion for serious medical applications and $25 billion to $60 billion for consumer medical applications [22]. - In China, over 2,000 patents related to BCI have been filed, indicating a growing interest and investment in this technology [23].